#BEGIN_DRUGCARD DB00194

# AHFS_Codes:
Not Available

# ATC_Codes:
J05AB03
S01AD06

# Absorption:
Systemetic absorption of vidarabine should not be expected to occur following ocular administration and swallowing lacrimal secretions.

# Biotransformation:
In laboratory animals, vidarabine is rapidly deaminated in the gastrointestinal tract to Ara-Hx.

# Brand_Mixtures:
Not Available

# Brand_Names:
Arasena-A
Spongoadenosine
Vidarabin
Vira-A

# CAS_Registry_Number:
24356-66-9

# ChEBI_ID:
45327

# Chemical_Formula:
C10H13N5O4

# Chemical_IUPAC_Name:
(2R,3S,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the vaccinia VIRUS and varicella zoster virus. [PubChem]

# Dosage_Forms:
Ointment	Ophthalmic

# Drug_Category:
Antimetabolites
Antiviral Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-2.115

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Vidarabine

# HET_ID:
RAB

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7+,10-/m1/s1

# InChI_Key:
InChIKey=OIRDTQYFTABQOQ-UHTZMRCNSA-N

# Indication:
For treatment of chickenpox - varicella, herpes zoster and herpes simplex

# KEGG_Compound_ID:
C07195

# KEGG_Drug_ID:
D00406

# LIMS_Drug_ID:
194

# Mechanism_Of_Action:
Vidarabine stops replication of herpes viral DNA in 2 ways: 1) competitive inhibition of viral DNA polymerase, and consequently 2) incorporation into and termination of the growing viral DNA chain.
This drug is a nucleoside analog and therefore has to be phosphorylated to be active. Vidarabine is sequentially phosphorylated by kinases to the triphosphate ara-ATP. This is the active form of vidarabine and is both an inhibitor and a substrate of viral DNA polymerase. When used as a substrate for viral DNA polymerase, ara-ATP competitively inhibits dATP leading to the formation of ‘faulty’ DNA. This is where ara-ATP is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
267.2413

# Molecular_Weight_Mono:
267.096753929

# Organisms_Affected:
Human Herpes Virus

# PDB_Experimental_ID:
1PW7

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451876

# Pharmacology:
Vidarabine is a synthetic purine nucleoside analogue with <i>in vitro</i> and <i>in vivo</i> inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV). The inhibitory activity of Vidarabine is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts Vidarabine into Vidarabine monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. <i>in vitro</i>, Vidarabine triphosphate stops replication of herpes viral DNA. When used as a substrate for viral DNA polymerase, Vidarabine triphosphate competitively inhibits dATP leading to the formation of 'faulty' DNA. This is where Vidarabine triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand.

# Predicted_LogP_Hydrophobicity:
-1.2

# Predicted_LogS:
-1.3

# Predicted_Water_Solubility:
1.40e+01 g/l

# Primary_Accession_No:
DB00194

# Protein_Binding:
24-38%

# PubChem_Compound_ID:
32326

# PubChem_Substance_ID:
46506630

# RxList_Link:
http://www.rxlist.com/cgi/generic3/vidarabine.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00333
EXPT02753

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
9-beta-D-arabinofuranosyl-adenine
Adenine Arabinoside
Ara-A
Ara-Atp
Araadenosine
Arabinoside Adenine
Arabinosyl Adenine
Arabinosyladenine

# Synthesis_Reference:
Not Available

# Toxicity:
Acute massive overdosage by oral ingestion of the ophthalmic ointment has not occurred. However, the rapid deamination to arabinosylhypoxanthine should preclude any difficulty. The oral LD<sub>50</sub> for vidarabine is greater than 5020 mg/kg in mice and rats. No untoward effects should result from ingestion of the entire contents of the tube. Overdosage by ocular instillation is unlikely because any excess should be quickly expelled from the conjunctival sac.

# Update_Date:
2013-02-08 16:19:10 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Vidarabine

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
ADA

# Phase_1_Metabolizing_Enzyme_1_ID:
3957

# Phase_1_Metabolizing_Enzyme_1_Name:
Adenosine deaminase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Adenosine deaminase
MAQTPAFDKPKVELHVHLDGSIKPETILYYGRRRGIALPANTAEGLLNVIGMDKPLTLPD
FLAKFDYYMPAIAGCREAIKRIAYEFVEMKAKEGVVYVEVRYSPHLLANSKVEPIPWNQA
EGDLTPDEVVALVGQGLQEGERDFGVKARSILCCMRHQPNWSPKVVELCKKYQQQTVVAI
DLAGDETIPGSSLLPGHVQAYQEAVKSGIHRTVHAGEVGSAEVVKEAVDILKTERLGHGY
HTLEDQALYNRLRQENMHFEICPWSSYLTGAWKPDTEHAVIRLKNDQANYSLNTDDPLIF
KSTLDTDYQMTKRDMGFTEEEFKRLNINAAKSSFLPEDEKRELLDLLYKAYGMPPSASAG
QNL

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P00813

# Drug_Target_1_Cellular_Location:
Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
16797734	Suzuki M, Okuda T, Shiraki K: Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61. Epub 2006 May 30.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
V01555

# Drug_Target_1_GenBank_ID_Protein:
1334913

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
BALF5

# Drug_Target_1_Gene_Sequence:
>3048 bp
TTAGAATGGTGGCCGGGCTGTAAAATTCTGGAGGACGGAGAGGGCGGCCCCGGAGTTGTT
ATCAAAGAGGCACTGGAGGATGTTGGCCGCTCCTTGGAGCAGCTTGTCGAAATAATGATC
CACGGCCACGGGAACGCCGTGCCGCTCGGCGTAGGCCGGGTCCTCGGCCATCTCCGTCTT
TCTCGCCCCCTTCACTCCCCCCTTGGGCTCCACAAAGACGTACTGGATGCGGTCGTGGAT
CTGGGGCAGTTCCTCGTTGCGCTCGACGAACTTCTGGTAGACGGCCAGGTGAGGCATCTG
GGTGCTCTTGTAGGCTGAGAGCTTGCGGCTGAGCTCCGTTGAAAAGCAGAGCTCCCCCAT
GGGGACCCTGCCTTCACGGAGGTCTGTGTAGGCCTGGTTTAGGATGTCAATGACGGGCAA
AAAGCCCACAGGTAGCCCTTGTGTAAATGACTCTTGGAAGGGCCGGTGGGAGAGGAGGCT
GGCCGCCTCCTTTACCCGGGCATCCGCCAGCACCAGGTCGAGCACGCGCCGGCAGCGTGT
CTGCACAAACTTGCAGGCCGTCTTCCGGACGAGCTCCACCCCCTTCATCAGGGTCTTGCC
GTCCGTCAGCACCCCCACATATCTCTTCTTTGTAATCAGCATCAGGCAGGAGAAGGTCTT
CTCGGCCTCCAGGGAGATGGGGGCCACAAACAGGCTCCGGGTGGTGTGGGCGGCCAGGGC
ATCGGCAAAGCGCAGGGTCTCGCTCTCTGAAAACCCCCGGCACTCGATAAACAGCGAGTC
CGTGTCCCCGTAGATGACTCGAAGCTGGCCCTCGGGGTTGAGGGGCGCCCAGGCGTCCGG
GGAGGGGGCCAGGGCCTGCAGGTTGGCGGGGCTCAGGGCCTCCACGAAGGCCTTGGCCCG
CTCCAACATCGTGCGGCCCTGCAGCGTCACCGTCTCGGCGATGGAGAGGCAGGGAAAGAG
GCCGTTGGCCACCCCGGTGAAGCCGTAGACGGCGTTGCACGTGCACTTGATGGCCAGCTG
CTGCTTGTCGAGGATGGTCCTTTGGCGCGGATCCTCGCAGGCCGCCAGCAGCTTCTTGAT
GGCCTTGCGCTTGGCCAGCCAGGAGGTCAACAGACTAGCCAAGAAGGACTCGTGCACGTG
CTTCTTTACAAAGTGGTAGACGCCCCCCGTGAGCCTGAAGGACTCATAGTCTTCTCCCGG
GCGCAGGCCGGCTAGCCTGTGCTCTTCTCCCGGCGTTATCATGGTAGAATAACAGAGATT
ATGAGCCTGAATGATGCTCGGGTAGAGGCTGGCAAAGTCCACCACCAGAACCGGGGAGTT
GTAGAATCCGGACAGGGGCTGGATGACGGTGGCCCCCTGGTAGCCGTCCCGGTCAGAGGC
CGAGGGCATGGGCAGGATAAAGTTTTCCTTTTGGGCGGCCGCCAGGAGGCAGGAGAACAC
GCGGATCTGCTGCCCATCGTCCAGCACCCGCCTGCAGGGGATGTGAGCGATCTTGGCAAT
CTCTGCCACCTCCACGTGGATCACGAAATGGTTTAGCAGATCCATGACCAGGGCCGAGTC
CTGCACGCAGTACATGCCGAGCCGCCTGCGCCCCTCGGGGCCCGCTGCAAAGAGGCGAGG
AATCTCCTTGTAATGCACATCCTCCTTCTTGGCCCCCAGTAGGTGCCTGGCTACTGTGTC
CAGCTTGTAGTCTGAGAGGCTGAGCTTGTCCCGGCACACGGCGTACATGTCGATGGGGAT
GAGGCCGGTGATGCGGACCTTGGTGTTGGCCCGCAAGAAGCCCTTGCCCGCATCATGGGG
TCGCCTGACCTCGCAGACGCCCCCAGCCCTAATTTTGCCCAGAGAGGCTGGGTTGATGCT
GTAGATGTGCCTGGCTCTGTCCAGAATGTAGGGCCAGTCAAAGTTGGCCACGTTGTAGCC
GGTCACAATCTCCACGCTGAGGTCTCTGATGAGCTGGAAGAAGGCGTAGAGCATGTCCAG
CTCCGATGGGAACTCGTAGACCTCAACCCCCTCTATGTCTTCGCAGGTGCCCAGCGTCAG
CAGGATGCGCCTATAGCGCCCGGCCTCCTCCCCTGTCGACCAGAGGACGCAGGATATCTG
CAGGATCAGGTCAGCCTCGTTGGTGGCCGTGGGGAAGCCCTCCTCCCCCAGACACTCGAT
ATCGAAGGCCAGGGCCTGGTAGGAGGGCCAGGAGCTGTCTTCACGCCGGACCGAGAGGTC
GCCCACCTCACAGTCGTACTCGAGCTCGGCGTACGAGTCCCGGTGCTGGAGGCGGGGGAT
GGCGCGGCGGCAGCTGTACCAGCCAAAGGTGACAAAGTCATTGTCCAGGACAAAGCGGCG
CGTGGCATCCACGTTGGCCTCAAAGATCCGACACCCGTGCTTGTCTTGCAGCCACGTGGC
CACGTGACACACACTGTTGGGATGGGAGAGGGTGATCTTGTGGTAGTCGCCGGCATGGTT
GCCGTAGCCCATAATGGAACGGCGCGTGACCTTCTCCACCGAGACCCGGCAGGGGGTCCT
GCGGTCGAAGGTGCTGGCCTTGAGGGCGCTGAGGACTGCAAACTCCACGTCCAGACCCTG
AGGCGCGCTGGCGTAGAAGTAGGCCTGCTGCCCAAACACGTTCACACACACGCTGGCCCC
ATCGGCCTTGCGCCGGCCCAGTAGCTTGATGACGATGCCACATGGCACCACATACCCCTG
TTTATCCGATGGAATGACGGCGCATTTCTCGTGCGTGTACACCGTCTCGAGTATGTCGTA
GACATGGAAGTCCAGAGGGCTTCCGTGGGTGTCTGCCTCCGGCCTTGCCGTGCCCTCTTG
GGCACGCTGGCGCCACCACATGCCCTTTCCATCCTCGTCACCCCCCACCACCGTCAGGGA
GTCTTGGTAGAAGCACAGGGGGGGCTGAGGCCCCCGCACATCCACCACCCCTGCGGCGCC
TGGTGTCTGGAAACACTTGGGAATGAGACGCAGGTACTCCTTGTCAGGCTTTTTCAGAAG
GCCTTTATTAGGTCTTAGGAAAGGGTTATAGAAGAGTCCCCCAGACAT

# Drug_Target_1_General_Function:
Replication, recombination and repair

# Drug_Target_1_General_References:
6087149	Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C, et al.: DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 1984 Jul 19-25;310(5974):207-11.
6092825	Bankier AT, Deininger PL, Farrell PJ, Barrell BG: Sequence analysis of the 17,166 base-pair EcoRI fragment C of B95-8 Epstein-Barr virus. Mol Biol Med. 1983 Jul;1(1):21-45.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4104

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
113419

# Drug_Target_1_Name:
DNA polymerase

# Drug_Target_1_Number_of_Residues:
1015

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00136	DNA_pol_B
PF03104	DNA_pol_B_exo

# Drug_Target_1_Protein_Sequence:
>DNA polymerase
MSGGLFYNPFLRPNKGLLKKPDKEYLRLIPKCFQTPGAAGVVDVRGPQPPLCFYQDSLTV
VGGDEDGKGMWWRQRAQEGTARPEADTHGSPLDFHVYDILETVYTHEKCAVIPSDKQGYV
VPCGIVIKLLGRRKADGASVCVNVFGQQAYFYASAPQGLDVEFAVLSALKASTFDRRTPC
RVSVEKVTRRSIMGYGNHAGDYHKITLSHPNSVCHVATWLQDKHGCRIFEANVDATRRFV
LDNDFVTFGWYSCRRAIPRLQHRDSYAELEYDCEVGDLSVRREDSSWPSYQALAFDIECL
GEEGFPTATNEADLILQISCVLWSTGEEAGRYRRILLTLGTCEDIEGVEVYEFPSELDML
YAFFQLIRDLSVEIVTGYNVANFDWPYILDRARHIYSINPASLGKIRAGGVCEVRRPHDA
GKGFLRANTKVRITGLIPIDMYAVCRDKLSLSDYKLDTVARHLLGAKKEDVHYKEIPRLF
AAGPEGRRRLGMYCVQDSALVMDLLNHFVIHVEVAEIAKIAHIPCRRVLDDGQQIRVFSC
LLAAAQKENFILPMPSASDRDGYQGATVIQPLSGFYNSPVLVVDFASLYPSIIQAHNLCY
STMITPGEEHRLAGLRPGEDYESFRLTGGVYHFVKKHVHESFLASLLTSWLAKRKAIKKL
LAACEDPRQRTILDKQQLAIKCTCNAVYGFTGVANGLFPCLSIAETVTLQGRTMLERAKA
FVEALSPANLQALAPSPDAWAPLNPEGQLRVIYGDTDSLFIECRGFSESETLRFADALAA
HTTRSLFVAPISLEAEKTFSCLMLITKKRYVGVLTDGKTLMKGVELVRKTACKFVQTRCR
RVLDLVLADARVKEAASLLSHRPFQESFTQGLPVGFLPVIDILNQAYTDLREGRVPMGEL
CFSTELSRKLSAYKSTQMPHLAVYQKFVERNEELPQIHDRIQYVFVEPKGGVKGARKTEM
AEDPAYAERHGVPVAVDHYFDKLLQGAANILQCLFDNNSGAALSVLQNFTARPPF

# Drug_Target_1_Reaction:
deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1)

# Drug_Target_1_SwissProt_ID:
P03198

# Drug_Target_1_SwissProt_Name:
DPOL_EBVB9

# Drug_Target_1_Synonyms:
EC 2.7.7.7

# Drug_Target_1_Theoretical_pI:
7.47

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Nucleus and mitochondria

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
Not Available

# Drug_Target_2_Gene_Sequence:
>Example: Dickerson dodecamer
CGCGAATTCGCG

# Drug_Target_2_General_Function:
Biological information storage and information transfer

# Drug_Target_2_General_References:
1234	Nadeau D, Marchand C: Change in the kinetics of sulphacetamide tissue distribution in Walker tumor-bearing rats. Drug Metab Dispos. 1975 Nov-Dec;3(6):565-76.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
874

# Drug_Target_2_Locus:
All loci

# Drug_Target_2_Molecular_Weight:
7656 (double strand)

# Drug_Target_2_Name:
DNA

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
1BNA

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
DNA + DNA polymerase + nNTP = 2 DNA + nNDP; DNA + RNA polymerase + NTP = mRNA + nNDP

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

# Drug_Target_2_SwissProt_ID:
Not Available

# Drug_Target_2_SwissProt_Name:
Not Available

# Drug_Target_2_Synonyms:
Deoxyribonucleic acid

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
12122323	Henrot A: [Mother-infant and indirect transmission of HSV infection: treatment and prevention] Ann Dermatol Venereol. 2002 Apr;129(4 Pt 2):533-49.
16797734	Suzuki M, Okuda T, Shiraki K: Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61. Epub 2006 May 30.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
Not Available

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
ORF36

# Drug_Target_3_Gene_Sequence:
Not Available

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
Not Available

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
7009

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
Not Available

# Drug_Target_3_Name:
Thymidine kinase

# Drug_Target_3_Number_of_Residues:
0

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
Not Available

# Drug_Target_3_Protein_Sequence:
Not Available

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
Not Available

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
P09250

# Drug_Target_3_SwissProt_Name:
KITH_VZVD

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
Not Available

# Drug_Target_3_Transmembrane_Regions:
Not Available

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
12122323	Henrot A: [Mother-infant and indirect transmission of HSV infection: treatment and prevention] Ann Dermatol Venereol. 2002 Apr;129(4 Pt 2):533-49.
16797734	Suzuki M, Okuda T, Shiraki K: Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61. Epub 2006 May 30.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AF243477

# Drug_Target_4_GenBank_ID_Protein:
8100965

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
TK

# Drug_Target_4_Gene_Sequence:
>1131 bp
ATGGCTTCGTACCCCTGCCATCAACACGCGTCTGCGTTCGACCAGGCTGCGCGTTCTCGC
GGCCATAGCAACCGACGTACGGCGTTGCGCCCTCGCCGGCAGCAAGAAGCCACGGAAGTC
CGCCTGGAGCAGAAAATGCCCACGCTACTGCGGGTTTATATAGACGGTCCTCACGGGATG
GGGAAAACCACCACCACGCAACTGCTGGTGGCCCTGGGTTCGCGCGACGATATCGTCTAC
GTACCCGAGCCGATGACTTACTGGCAGGTGCTGGGGGCTTCCGAGACAATCGCGAACATC
TACACCACACAACACCGCCTCGACCAGGGTGAGATATCGGCCGGGGACGCGGCGGTGGTA
ATGACAAGCGCCCAGATAACAATGGGCATGCCTTATGCCGTGACCGACGCCGTTCTGGCT
CCTCATATCGGGGGGGAGGCTGGGAGCTCACATGCCCCGCCCCCGGCCCTCACCCTCATC
TTCGACCGCCATCCCATCGCCGCCCTCCTGTGCTACCCGGCCGCGCGATACCTTATGGGC
AGCATGACCCCCCAGGCCGTGCTGGCGTTCGTGGCCCTCATCCCGCCGACCTTGCCCGGC
ACAAACATCGTGTTGGGGGCCCTTCCGGAGGACAGACACATCGACCGCCTGGCCAAACGC
CAGCGCCCCGGCGAGCGGCTTGACCTGGCTATGCTGGCCGCGATTCGCCGCGTTTACGGG
CTGCTTGCCAATACGGTGCGGTATCTGCAGGGCGGCGGGTCGTGGCGGGAGGATTGGGGA
CAGCTTTCGGGGACGGCCGTGCCGCCCCAGGGTGCCGAGCCCCAGAGCAACGCGGGCCCA
CGACCCCATATCGGGGACACGTTATTTACCCTGTTTCGGGCCCCCGAGTTGCTGGCCCCC
AACGGCGACCTGTATAACGTGTTTGCCTGGGCCTTGGACGTCTTGGCCAAACGCCTCCGT
CCCATGCACGTCTTTATCCTGGATTACGACCAATCGCCCGCCGGCTGCCGGGACGCCCTG
CTGCAACTTACCTCCGGGATGGTCCAGACCCACGTCACCACCCCAGGCTCCATACCGACG
ATCTGCGACCTGGCGCGCACGTTTGCCCGGGAGATGGGGGAGGCTAACTGA

# Drug_Target_4_General_Function:
Involved in thymidine kinase activity

# Drug_Target_4_General_References:
10878078	Nagamine M, Suzutani T, Saijo M, Hayashi K, Azuma M: Comparison of polymorphism of thymidine kinase gene and restriction fragment length polymorphism of genomic DNA in herpes simplex virus type 1. J Clin Microbiol. 2000 Jul;38(7):2750-2.
10882609	Morfin F, Souillet G, Bilger K, Ooka T, Aymard M, Thouvenot D: Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J Infect Dis. 2000 Jul;182(1):290-3. Epub 2000 Jun 19.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
509

# Drug_Target_4_Locus:
-

# Drug_Target_4_Molecular_Weight:
40897

# Drug_Target_4_Name:
Thymidine kinase

# Drug_Target_4_Number_of_Residues:
376

# Drug_Target_4_PDB_ID:
1OF1

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00693	Herpes_TK

# Drug_Target_4_Protein_Sequence:
>Thymidine kinase
MASYPCHQHASAFDQAARSRGHSNRRTALRPRRQQEATEVRLEQKMPTLLRVYIDGPHGM
GKTTTTQLLVALGSRDDIVYVPEPMTYWQVLGASETIANIYTTQHRLDQGEISAGDAAVV
MTSAQITMGMPYAVTDAVLAPHIGGEAGSSHAPPPALTLIFDRHPIAALLCYPAARYLMG
SMTPQAVLAFVALIPPTLPGTNIVLGALPEDRHIDRLAKRQRPGERLDLAMLAAIRRVYG
LLANTVRYLQGGGSWREDWGQLSGTAVPPQGAEPQSNAGPRPHIGDTLFTLFRAPELLAP
NGDLYNVFAWALDVLAKRLRPMHVFILDYDQSPAGCRDALLQLTSGMVQTHVTTPGSIPT
ICDLARTFAREMGEAN

# Drug_Target_4_Reaction:
ATP + thymidine = ADP + thymidine 5'-phosphate

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
In latent infection, may allow the virus to be reactivated and to grow in cells lacking a high concentration of phosphorylated nucleic acid precursors, such as nerve cells that do not replicate their genome

# Drug_Target_4_SwissProt_ID:
Q9QNF7

# Drug_Target_4_SwissProt_Name:
KITH_HHV1

# Drug_Target_4_Synonyms:
EC 2.7.1.21

# Drug_Target_4_Theoretical_pI:
7.70

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB00194
